BioCryst Pharma (BCRX) Tops Q3 EPS by 8c

BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.12), $0.08 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $2.11 million.

Cash, cash equivalents and investments totaled $127.6 million at September 30, 2014, compared to $40.8 million at December 31, 2013. This significant increase in cash and investments resulted from the Company's successful June public offering of common stock.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c